WorldPharmaNews
Search ...
Home
Business
Research
Events
Regulatory
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
www.bms.com
.
Bristol-Myers Squibb RSS Channel
Filters
Display #
5
10
15
20
25
30
50
100
All
Filter
List of articles in category Bristol-Myers Squibb
Title
Published Date
Bristol-Myers Squibb and Ambrx Announce Collaboration
22 September 2011
Bristol-Myers Squibb and Ono Enter into Strategic Agreement
21 September 2011
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
09 September 2011
Bristol-Myers Squibb Delivers Excellent Second Quarter
05 August 2011
Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
22 July 2011
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
21 July 2011
Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
07 July 2011
Bristol-Myers Squibb to Expand Access to Reyataz® in sub-Saharan Africa and India
29 June 2011
Bristol-Myers Squibb Foundation Awards $1.5 Million in Grants
27 June 2011
Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement
03 June 2011
Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval
29 April 2011
Phase III Study of Investigational Compound Ipilimumab Achieves Primary Endpoint
22 March 2011
Bristol-Myers Squibb Delivers Solid Fourth Quarter Results
27 January 2011
Pediatric Exclusivity For PLAVIX®
25 January 2011
People to Actively Manage Their Type 2 Diabetes
11 January 2011
KOMBIGLYZE™ XR Now Available in U.S. Pharmacies
09 January 2011
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement
21 December 2010
Encouraging Phase 2 Interim Data for Elotuzumab in Relapsed Multiple Myeloma
07 December 2010
Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration
01 December 2010
APPRAISE-2 Study with Investigational Compound Apixaban Discontinued
21 November 2010
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
Business & Industry
Insilico Medicine brings AI-powered "ChatPandaGPT" to its target discovery platform
BlueRock Therapeutics to incorporate wearable and invisible contactless digital health technologies from Rune Labs and Emerald Innovations in Parkinson's disease clinical trial
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma
AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge
Pfizer invests $43 billion to battle cancer
Research & Development
'Biohybrid' device could restore function in paralysed limbs
Scientists use tardigrade proteins for human health breakthrough
DNA treatment could delay paralysis that strikes nearly all patients with ALS
Scientists reveal a potential new approach to treating liver cancer
Normalizing tumor blood vessels may improve immunotherapy against brain cancer
Engineered bacteria find tumors, then alert the authorities
First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases
Conferences & Events
SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
SAE Media Group's 6th annual 3D Cell Culture Conference
CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
CPHI Excellence in Pharma Award Winners 2022
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
FDA grants Accelerated Approval for Alzheimer's disease treatment
FDA approves new HIV drug for adults with limited treatment options
FDA approves first gene therapy for the treatment of high-risk, non-muscle-invasive bladder cancer
FDA approves first gene therapy to treat adults with Hemophilia B
FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
You are here:
Home
Bristol-Myers Squibb